MDGL - Madrigal sees 'tremendous interest' in new NASH drug Rezdiffra
2024-05-07 10:44:37 ET
More on Madrigal Pharmaceuticals
- Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
- Madrigal: Accelerated Rezdiffra Approval Puts It In The NASH Lead
- Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18
- Madrigal announces US launch of NASH/MASH drug Rezdiffra